Bicycle Therapeutics to Present Preclinical Data on Lead Molecule BT1718 at the AACR-NCI-EORTC International Cancer Conference
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today that the company will present data describing the mechanism of action of BT1718, Bicycle’s lead molecule, which is being developed to target cancers of high unmet need including triple negative breast cancer and non small cell lung cancer. The data will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Philadelphia, Pennsylvania from October 26 – 30, 2017.
Details for the poster presentation, which will be given by Gavin Bennett, Ph.D., Bicycle’s Head of Preclinical Development, are as follows:
Title: The mechanism of action of BT1718, a
novel small-molecule drug conjugate for the treatment of solid tumors
expressing MT1-MMP
Session: PO.B20 –
Therapeutic Agents: Other Topics
Poster #:
B135
Date & Time: Sunday, October
29, 2017, 12:30 – 4:00 p.m. ET
About Bicycle Therapeutics
Bicycle Therapeutics is
developing a unique class of chemically synthesized medicines based on
its proprietary bicyclic peptide (Bicycle®) product platform to
address therapeutic needs unreachable with existing treatment
modalities. Bicycle’s internal focus is in oncology, where the company
is developing targeted cytotoxics (Bicycle Toxin Conjugates),
targeted innate immune activators and T-cell modulators for cancers of
high unmet medical need. Bicycles’ small size and exquisite targeting
delivers rapid tumor penetration and retention while clearance rates and
routes can be tuned to minimize exposure of healthy tissue and bystander
toxicities. The company’s lead program, BT718, is rapidly advancing
towards the clinic in collaboration with Cancer Research, UK. The
company’s unique intellectual property is based on the work initiated at
the MRC Laboratory of Molecular Biology in Cambridge, U.K., by the
scientific founders of the company, Sir Gregory Winter and Professor
Christian Heinis. Bicycle has its headquarters in Cambridge, U.K., with
many key functions and members of its leadership team located in the
biotech hub of Boston, Mass. For more information, visit www.bicycletherapeutics.com
or follow us on Twitter at @Bicycle_tx.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171026005229/en/
Ten Bridge Communications (U.S.)
Sarah Sutton, +1-518-932-3680
Sarah@tenbridgecommunications.com
